查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1837129

旅行疫苗市場（按疫苗類型、劑型、年齡層和最終用戶分類）—2025-2032 年全球預測

Travel Vaccines Market by Vaccine Type, Form, Age Group, End User - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 194 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，旅行疫苗市場將成長 200 億美元，複合年成長率為 10.36%。

主要市場統計數據
基準年2024年 90.9億美元
預計2025年 100.1億美元
預測年份：2032年 200億美元
複合年成長率（%） 10.36%

簡潔而權威的框架解釋了為什麼隨著旅行模式的增加和旅行者期望的變化，旅行疫苗接種仍然至關重要

隨著跨境旅行的恢復和多樣化，旅行相關疫苗接種已成為一項至關重要的公共衛生干預措施。旅行前接種疫苗可以預防與旅遊、商務旅行、出國目的地和人道主義部署相關的疫苗可預防疾病的傳播，從而保護旅行者本人和更廣泛的目的地社區。當旅客在準備旅行時，會參考臨床指南、目的地特定的入境要求和數位健康資訊；這些因素正在影響對包括肝炎、流感和黃熱病在內的關鍵疫苗的需求模式。

臨床醫生和公共衛生部門不斷根據新出現的流行病學數據和不斷變化的旅行者特徵調整疫苗通訊協定。醫療旅遊和國際任務的增加推動了對便捷獲取專用疫苗和可靠的暴露後預防措施的需求，尤其是針對狂犬病和傷寒等疾病。同時，消費者行為正轉向便利和數位化服務，越來越多的旅客尋求遠端醫療旅行前諮詢、快速獲取疫苗接種記錄以及透過藥局和線上管道付款。這些趨勢凸顯了整合臨床指導、供應鏈韌性和患者導向的技術以提供可靠且便利的旅遊疫苗接種服務的重要性。

科學創新、數位化和監管複雜性如何融合重塑全球旅行疫苗接種模式和相關人員策略

在疫苗科學的進步、數位醫療的整合以及塑造供應鏈的地緣政治力量的推動下，旅行疫苗接種格局正在發生重大變化。包括新平台和改進的低溫運輸解決方案在內的技術進步，使得疫苗製劑更加耐用且適應性更強，從而影響了疫苗接種計劃、儲存要求和分發方式。同時，用於疫苗接種記錄保存、旅行前風險評估和預約安排的數位醫療工具正在再形成患者病人歷程，並拓展傳統臨床環境之外的網路基地台。

不同司法管轄區的監管一致性正在提高，但仍不均衡，這促使行業相關人員採取更靈活的合規策略，並投資於跨境資料互通性。同時，公眾對疫苗安全性和有效性的審查日益嚴格，這推動了臨床醫生和製造商之間清晰、基於證據的溝通需求。因此，各組織正在優先考慮建立信任的措施、透明的供應鏈實踐以及與當地醫療保健提供者的夥伴關係，以確保在疫情風險發生變化時能夠做好準備並快速回應。這種結構性轉變需要一種更一體化的方法，將科學創新、數位化和彈性物流結合，以有效滿足旅行者的需求。

檢驗進口關稅波動對旅遊疫苗接種網路採購、低溫運輸物流和服務提供的連鎖反應

貿易和海關制度的政策變化可能會對支持旅行疫苗接種計劃的疫苗及相關物資的物流和供應產生重大影響。隨著疫苗成分、包裝材料和低溫運輸設備的進口關稅上調，整個供應鏈的相關人員會調整其採購和庫存策略，以消化成本壓力或保護淨利率。製造商和經銷商可能會重新評估供應商契約，加快本地化進程，或優先儲備關鍵投入品，以緩解供應中斷的影響。

這些調整也將波及營運流動診所、醫院疫苗接種計畫和零售藥局管道的服務供應商。營業利潤率較低的診所可能會重新定價其服務，協商不同的供應條款，並儘可能轉向採購國內替代品。同時，貨運和物流合作夥伴必須調整路線和倉儲策略，以控制成本，同時保持對溫度敏感的完整性。從策略角度來看，持續的關稅波動鼓勵相關人員實現供應商多元化，提高採購透明度，並積極與政策制定者合作，以明確豁免條款和統一標準。事實上，貿易政策波動強化了在臨床、商業和監管領域制定應急計畫的必要性，以維持可靠的旅遊疫苗及相關服務。

實際可行的細分洞察，強調疫苗類型、交付方式、年齡層和最終用戶管道必須如何體現在差異化的臨床和商業策略中

細緻地了解細分市場對於協調整個旅行疫苗接種生態系統的臨床指導、分發方法和商業策略至關重要。疫苗類型組合至關重要，因為不同的病原體和疫苗接種方案（包括甲型肝炎、乙型肝炎、流感、腦膜炎球菌病菌感染、狂犬病、傷寒和黃熱病）在臨床緊迫性、旅行前接種時間和儲存注意事項方面有所不同。雖然注射劑型因其有效性和既定的給藥方案在臨床實踐中占主導地位，但口服疫苗為某些旅行者群體提供了替代途徑，並有助於在資源匱乏和偏遠地區推廣。

成年旅客通常需要定期加強注射和針對出國目的地的疫苗接種，而兒童旅客則需要根據年齡選擇合適的劑量、知情同意途徑，並納入常規兒童免疫接種計畫。終端用戶細分會影響疫苗的分發和獲取：醫院和診所負責處理複雜的臨床病例和專科疫苗接種，藥房提供便捷的門診就診和續藥服務，旅行診所負責協調旅行前風險評估和多劑量接種計劃，而在線藥房則通過宅配和數字記錄同步來擴大範圍。透過根據這些細分維度調整產品系列、服務模式和患者參與策略，相關人員可以提高覆蓋率，減少疫苗接種流失，並改善整體旅客體驗。

美洲、歐洲、中東和非洲以及亞太市場的區域動態及其對旅客疫苗供應的實際影響

地理因素決定了疾病的流行程度、法律規範和服務提供模式，因此需要針對特定區域制定旅行者疫苗接種方案。在美洲，公共衛生系統和私人醫療機構正在合作應對南美洲部分地區的地方性疾病風險，例如黃熱病，並支持與旅行模式相契合的大規模季節性流感防治宣傳活動。該地區還展示了先進的分銷網路，並日益普及數位健康證書，為跨區域旅行的旅客提供更無縫的旅行前通關和疫苗接種後文件記錄。

歐洲、中東和非洲的監管環境各異，臨床能力也參差不齊。雖然一些歐洲國家維持嚴格的旅行前諮詢服務和集中疫苗接種計劃，但非洲部分地區在低溫運輸基礎設施和獲得專用疫苗方面持續面臨挑戰。中東是客流量大的關鍵中繼站，更凸顯了疫苗接種驗證和疫情防範的重要性。亞太地區的特點是部分市場製造能力強大，出境觀光需求不斷成長，某些次區域持續存在傷寒和狂犬病等地方性疾病問題。該地區的數位醫療應用和私營部門創新也呈現快速成長，支持透過藥局和遠端醫療旅遊診所擴大醫療服務覆蓋範圍。了解這些地區差異可以更有效地分配臨床資源、有針對性的公共衛生訊息訊息，並建立反映當地需求和能力的策略夥伴關係。

領先的製造商、經銷商和服務提供者如何重組其投資組合、夥伴關係和營運彈性，以確保旅遊疫苗接種的部署

行業參與者正在透過調整產品組合、擴大經銷夥伴以及投資製造和物流能力來應對臨床需求和商業性機會。領先的疫苗製造商和產品創新者正在擴展開發平臺，以應對旅行相關的病原體多樣性，並提高製劑穩定性和給藥便利性。同時，經銷商和服務提供者正在與專業的旅行診所和藥房網路建立更緊密的合作，以簡化預約安排、低溫運輸處理和記錄保存流程。

商業策略越來越注重韌性和靈活性。企業正在探索產能共享協議、區域灌裝和成品營運以及分級定價機制，以應對採購的差異性。與數位平台提供者建立策略聯盟，可實現全面旅行前評估、自動多劑量提醒以及在照護現場無縫驗證疫苗接種狀態。此外，品質保證和監管準備仍然是企業計劃的核心，企業正在投資強大的藥物安全檢測和市場支持，以維護臨床醫生的信心並應對複雜的跨司法管轄區核准途徑。

為產業領導者提供切實可行的優先策略行動，以增強供應彈性、數位存取和相關人員協作

旅行疫苗生態系統的領導者應優先考慮一系列切實可行的行動，以加強臨床服務的提供和商業性可行性。首先，投資供應鏈冗餘和低溫運輸最佳化，以降低貿易政策衝擊和物流中斷帶來的脆弱性。其次，透過實施可互通的疫苗接種記錄、遠端醫療旅行前評估以及自動預約和用藥提醒，加速整個旅行者旅程的數位整合，以提高接種率並最大限度地減少錯失良機。

第三，根據疫苗類型、劑型、年齡層和最終用戶特徵客製化產品類型和分銷管道，從而根據細分市場和本地需求客製化參與模式。第四，透過在製造商、經銷商、旅行診所和藥房網路之間建立策略夥伴關係，加強相關人員合作，從而協調應對疫情風險並簡化患者獲取疫苗的流程。第五，加強公眾傳播策略，透過基於證據的訊息通訊、臨床醫生培訓以及針對高風險旅行群體的有針對性的推廣工作，解決猶豫不決的問題。最後，將監管和政策參與納入計劃，以影響關稅和貿易談判，盡可能爭取豁免，並支持統一的標準，以促進疫苗跨境流動和核准。

結合初步訪談、政策審查和供應鏈分析的嚴格混合方法研究途徑為旅行疫苗接種提供了實用見解

這些見解背後的研究採用了混合方法，旨在了解旅行疫苗接種的臨床、操作和政策層面。主要定性訪談對象包括臨床醫生、旅遊醫學專家、供應鏈經理和監管專家，旨在收集有關服務提供挑戰和適應性調整的第一手資料。此外，還整合了來自同行評審文獻、公共衛生機構指南、貿易政策文件和物流報告的二手訊息，以檢驗臨床路徑、儲存要求以及影響跨境疫苗運輸的監管環境。

我們的分析方法將訪談記錄的主題分析與供應鏈圖譜結合，對重點地區進行比較性政策審查。三角測量程序確保報告結果與多個獨立資訊來源一致，且結論反映的是趨同證據，而非單一資訊來源的假設。我們也考慮了調查方法的限制。雖然定性的深入探索提供了詳細的營運訊息，相關人員的觀點可能因市場和亞群而異，監管條件也可能因政策的快速變化而改變。為了解決這個問題，我們的研究與臨床顧問和物流合作夥伴共同製定了持續的檢驗查核點，以確保洞察的實用性和時效性。

結論性綜合結果強調了維持疫苗接種管道、增強抵禦能力以及協調整個旅行疫苗接種生態系統中相關人員行動的戰略重點

維持可靠且可近的旅遊疫苗接種服務需要臨床、商業和政策領域協調一致的行動。科學創新、數位轉型和不斷發展的貿易政策的匯聚力量，為管理疫苗供應和配送的相關人員創造了機遇，也帶來了脆弱性。有效應對這種環境需要積極主動的供應鏈策略、尊重差異化細分的有針對性的患者參與，以及反映當地流行病學和監管環境的客製化方法。

投資於免疫接種記錄互通性、加強跨分銷管道夥伴關係並與政策制定者進行建設性溝通的組織，將更有能力在風險變化時保持可及性並有效應對。重要的是，清晰的溝通和臨床醫生主導的教育仍然是維護公眾信任和確保旅行者及時獲得循證預防措施的基礎。透過將策略遠見與營運策略結合，相關人員可以推進有韌性且公平的免疫接種服務，同時保持旅行者照護的連續性。

目錄

第1章：前言

第2章調查方法

第3章執行摘要

第4章 市場概況

第5章 市場洞察

  • 採用mRNA平台技術加速長效型旅遊疫苗的開發
  • 將數位疫苗接種護照和生物識別納入旅行前健康通訊協定
  • 基於旅行者免疫遺傳學和健康風險分析的個人化疫苗接種計劃的興起
  • 擴大官民合作關係，在新興市場建立全球旅行疫苗接種中心
  • 引進新一代耐熱疫苗，改善偏遠地區低溫運輸物流
  • 對於前往多個國家的旅客來說，涵蓋多種地方病的聯合疫苗的需求日益成長。
  • 利用遠端醫療平台提供旅行前遠距諮詢和疫苗推薦服務
  • 監管協調努力對簡化跨境疫苗核准流程的影響
  • 為國際疫苗分銷開發環保且永續的包裝解決方案
  • 疫情後旅行激增對疫苗接種資源分配和優先策略的影響

第6章：2025年美國關稅的累積影響

第7章：人工智慧的累積影響，2025年

8. 旅行疫苗市場（依疫苗類型）

  • 甲型肝炎
  • B型肝炎
  • 流感
  • 腦膜炎奈瑟菌
  • 狂犬病
  • 傷寒
  • 黃熱病

9. 旅行疫苗市場（按類型）

  • 注射
  • 口服

第10章旅行疫苗市場（依年齡層）

  • 成人
  • 孩子們

第 11 章。旅行疫苗市場（按最終用戶分類）

  • 醫院和診所
  • 網路藥局
  • 藥局
  • 旅行診所

12. 旅行疫苗市場（按地區）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第 13 章旅行疫苗市場（按類別）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

14. 旅行疫苗市場（依國家）

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第15章競爭格局

  • 2024年市佔率分析
  • 2024年FPNV定位矩陣
  • 競爭分析
    • Sanofi SA
    • GlaxoSmithKline plc
    • Merck & Co., Inc.
    • Pfizer Inc.
    • Takeda Pharmaceutical Company Limited
    • Valneva SE
    • Bavarian Nordic A/S
    • Bharat Biotech International Limited
    • Serum Institute of India Private Limited
    • Perusahaan Umum（Persero）Bio Farma
Product Code: MRR-0316851957A3

The Travel Vaccines Market is projected to grow by USD 20.00 billion at a CAGR of 10.36% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 9.09 billion
Estimated Year [2025] USD 10.01 billion
Forecast Year [2032] USD 20.00 billion
CAGR (%) 10.36%

A concise and authoritative framing of why travel immunization remains essential amid rising mobility patterns and shifting traveler expectations

Travel-related immunization remains a critical public health intervention as cross-border mobility resumes and diversifies. Pre-travel vaccination practices protect both individual travelers and broader host communities by limiting transmission of vaccine-preventable diseases associated with tourism, business travel, migration, and humanitarian deployments. Travelers consult an evolving mix of clinical guidelines, destination-specific entry requirements, and digital health credentials when preparing for trips, and these factors shape demand patterns for core vaccines such as hepatitis, influenza, and yellow fever.

Clinicians and public health authorities continue to adapt vaccination protocols to align with emerging epidemiological data and shifting traveler profiles. The growing prevalence of medical tourism and expatriate assignments has amplified the need for streamlined access to specialized vaccines and reliable post-exposure prophylaxis, particularly for diseases such as rabies and typhoid. Meanwhile, consumer behavior has shifted toward convenience and digital-enabled services, with more travelers seeking pre-travel consultations through telemedicine, rapid access to immunization records, and fulfillment via pharmacies and online channels. These dynamics underscore the importance of integrating clinical guidance, supply chain resilience, and patient-facing technologies to deliver dependable and accessible travel vaccination services.

How scientific innovation, digital enablement, and regulatory complexity are converging to reshape global travel vaccination delivery models and stakeholder strategies

The travel vaccine landscape is undergoing transformative shifts driven by advances in vaccine science, digital health integration, and the geopolitical context that shapes supply chains. Technological progress, including novel platforms and improved cold-chain solutions, is enabling more durable and adaptable vaccine formulations, which in turn affects vaccination schedules, storage requirements, and distribution approaches. Concurrently, digital health tools for vaccination record-keeping, pre-travel risk assessment, and appointment scheduling are reshaping patient journeys and expanding access points beyond traditional clinical settings.

Regulatory alignment across jurisdictions is improving but remains uneven, prompting industry stakeholders to adopt more flexible compliance strategies and to invest in cross-border data interoperability. In parallel, heightened public scrutiny around vaccine safety and efficacy has intensified the need for clear, evidence-based communication from clinicians and manufacturers. As a result, organizations are prioritizing trust-building measures, transparent supply-chain practices, and partnerships with local providers to ensure both preparedness and rapid response capability when outbreak risks change. These structural shifts collectively require a more integrated approach that combines scientific innovation, digital enablement, and resilient logistics to meet traveler needs effectively.

Examining the ripple effects of altered import tariff dynamics on procurement, cold-chain logistics, and service delivery across travel immunization networks

Policy changes in trade and tariff regimes can materially influence the logistics and availability of vaccines and associated supplies that support travel immunization programs. When import duties or tariffs increase on vaccine components, packaging materials, or cold-chain equipment, actors across the supply chain adjust procurement and inventory strategies to absorb cost pressures or to preserve margin. Manufacturers and distributors may re-evaluate supplier contracts, accelerate localization efforts, or prioritize stockpiling of critical inputs to mitigate disruption.

These adjustments cascade to service providers who operate travel clinics, hospital immunization programs, and retail pharmacy channels. Clinics with narrow operating margins may revise service pricing, negotiate different supply terms, or shift sourcing toward domestically produced alternatives where feasible. At the same time, freight and logistics partners must adapt routing and warehousing strategies to maintain temperature-sensitive integrity while controlling costs. From a strategic standpoint, sustained tariff changes prompt stakeholders to strengthen vendor diversification, increase transparency in procurement, and engage proactively with policymakers to clarify exemptions and harmonized standards. In effect, trade policy volatility amplifies the need for contingency planning across clinical, commercial, and regulatory frontiers to maintain reliable access to travel vaccines and related services.

Actionable segmentation insights that clarify how vaccine type, delivery form, age groups, and end-user channels must inform differentiated clinical and commercial strategies

A nuanced understanding of segmentation is essential for tailoring clinical guidance, distribution approaches, and commercial strategies across the travel vaccination ecosystem. Vaccine type composition matters because different pathogens and immunization regimens-such as those for hepatitis A and B, influenza, meningococcal disease, rabies, typhoid, and yellow fever-carry distinct clinical urgency, pre-travel timing, and storage considerations; therefore, supply prioritization and clinician workflows must reflect these clinical differences. Form factors influence delivery logistics and patient preference, as injectable formulations dominate in clinical settings due to efficacy and established administration protocols, while oral vaccines offer alternative pathways for certain traveler groups and can ease outreach in low-resource or remote scenarios.

Age group segmentation creates divergent clinical pathways and communication needs; adult travelers commonly require routine boosters or destination-specific immunizations, whereas pediatric travelers demand age-appropriate dosing, consent pathways, and integration with routine childhood vaccination schedules. End-user segmentation affects distribution and access: hospitals and clinics handle complex clinical cases and specialist immunizations, pharmacies offer convenient walk-in access and replenishment, travel clinics provide tailored pre-travel risk assessment and multi-dose schedules, and online pharmacies extend reach through home delivery and digital record synchronization. By aligning product portfolios, service models, and patient engagement tactics to these segmentation dimensions, stakeholders can enhance coverage, reduce missed opportunities for vaccination, and improve the overall traveler experience.

Regional dynamics and practical implications for travel vaccine delivery across the Americas, Europe Middle East & Africa, and Asia-Pacific markets

Geographic context shapes disease prevalence, regulatory frameworks, and service delivery models, requiring region-specific approaches to travel vaccination. In the Americas, public health systems and private providers coordinate to address endemic risks such as yellow fever in parts of South America and to support large-scale seasonal influenza campaigns that intersect with travel patterns. This region also demonstrates advanced distribution networks and a growing adoption of digital health credentials, enabling more seamless pre-travel clearance and post-vaccination documentation for travelers moving between subregions.

Europe, the Middle East, and Africa present a diverse regulatory landscape and a wide range of clinical capacities. Several European countries maintain rigorous pre-travel advisory services and centralized vaccination programs, while parts of Africa face persistent challenges related to cold-chain infrastructure and access to specialized vaccines. The Middle East is an important transit corridor with high passenger throughput, which elevates the importance of vaccination verification and outbreak preparedness. Asia-Pacific is characterized by robust manufacturing capability in some markets, rising demand driven by outbound tourism, and persistent endemic concerns such as typhoid and rabies in specific subregions. The region also shows rapid growth in digital health adoption and private-sector innovation, which supports expanded access through pharmacies and telehealth-enabled travel clinics. Understanding these regional differences enables more effective allocation of clinical resources, targeted public health messaging, and strategic partnerships that reflect local needs and capacities.

How leading manufacturers, distributors, and service providers are reshaping portfolios, partnerships, and operational resilience to secure travel vaccination delivery

Industry participants are responding to both clinical imperatives and commercial opportunities by adapting portfolios, extending distribution partnerships, and investing in manufacturing and logistics capabilities. Leading vaccine producers and product innovators are expanding their development pipelines to address travel-related pathogen diversity and to improve formulation stability and administration convenience. At the same time, distributors and service providers are forging closer collaborations with specialty travel clinics and pharmacy networks to streamline appointment scheduling, cold-chain handling, and record-keeping.

Commercial strategies increasingly emphasize resilience and flexibility: companies are exploring capacity-sharing agreements, regional fill-and-finish operations, and tiered pricing mechanisms to address procurement variability. Strategic alliances with digital platform providers enable integrated pre-travel assessments, automated reminders for multi-dose series, and smoother verification of immunization status at points of care. Additionally, quality assurance and regulatory readiness remain central to company planning, with firms investing in robust pharmacovigilance and in-market support to sustain clinician confidence and to navigate complex approval pathways across jurisdictions.

Practical and prioritized strategic actions that industry leaders should implement to reinforce supply resilience, digital access, and targeted stakeholder collaboration

Leaders in the travel vaccine ecosystem should prioritize a set of practical actions that strengthen clinical service delivery and commercial viability. First, invest in supply chain redundancy and cold-chain optimization to reduce vulnerability to trade policy shocks and logistical disruptions; this includes establishing alternative suppliers, regional fill-and-finish capabilities, and transparent inventory management systems. Second, accelerate digital integration across the traveler journey by deploying interoperable vaccination records, telemedicine pre-travel assessments, and automated appointment and dosing reminders to increase uptake and minimize missed opportunities.

Third, tailor engagement models to segmentation and regional needs by aligning product offerings and distribution channels with vaccine type, form, age group, and end-user characteristics. Fourth, enhance stakeholder collaboration by building strategic partnerships among manufacturers, distributors, travel clinics, and pharmacy networks to enable coordinated response to outbreak risks and to streamline patient access. Fifth, strengthen public communication strategies to address hesitancy through evidence-based messaging, clinician training, and targeted outreach for high-risk traveler cohorts. Finally, embed regulatory and policy engagement in planning to influence tariff and trade discussions, secure exemptions where possible, and support harmonized standards that facilitate cross-border vaccine movement and recognition.

A rigorous mixed-methods research approach combining primary interviews, policy review, and supply-chain analysis to underpin practical travel vaccination insights

The research underpinning these insights employed a mixed-methods approach designed to capture clinical, operational, and policy dimensions of travel immunization. Primary qualitative interviews were conducted with clinicians, travel-medicine specialists, supply-chain managers, and regulatory experts to gather direct observations about service delivery challenges and adaptation strategies. Secondary source synthesis drew on peer-reviewed literature, public health agency guidance, trade policy documents, and logistics reports to validate clinical pathways, storage requirements, and the regulatory context affecting cross-border vaccine movement.

Analytical methods combined thematic analysis of interview transcripts with supply-chain mapping and comparative policy review across the principal regions. Triangulation procedures ensured that reported findings aligned with multiple independent information sources and that conclusions reflected convergent evidence rather than single-source assumptions. The methodology also accounted for limitations: while qualitative depth provided rich operational detail, stakeholder perspectives may vary by market and subpopulation, and rapid policy changes can alter regulatory conditions. To address this, the research incorporated continuous validation checkpoints with clinical advisors and logistics partners to ensure practical relevance and timeliness of insights.

Conclusive synthesis emphasizing strategic priorities for preserving access, building resilience, and aligning stakeholder actions across the travel vaccination ecosystem

Maintaining reliable and accessible travel immunization services requires coordinated action across clinical, commercial, and policy domains. The converging forces of scientific innovation, digital transformation, and evolving trade policy create both opportunities and vulnerabilities for stakeholders who manage vaccine supply and delivery. Effectively navigating this environment demands proactive supply-chain strategies, targeted patient engagement that respects segmentation differences, and regionally tailored approaches that reflect local epidemiology and regulatory conditions.

Organizations that invest in interoperability of vaccination records, strengthen partnerships across distribution channels, and engage constructively with policymakers will be better positioned to sustain access and to respond efficiently when risks change. Importantly, clear communication and clinician-led education remain foundational for maintaining public trust and for ensuring that travelers receive timely, evidence-based protection. By aligning operational tactics with strategic foresight, stakeholders can preserve continuity of care for travelers while advancing resilient and equitable vaccination services.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Adoption of mRNA platform technologies to accelerate development of long-lasting travel vaccines
  • 5.2. Integration of digital vaccination passports and biometric verification in pre-travel health protocols
  • 5.3. Rise of personalized vaccination schedules based on traveler immunogenetic and health risk profiling
  • 5.4. Expansion of public private partnerships to establish global travel vaccination hubs in emerging markets
  • 5.5. Implementation of next generation thermostable vaccines to improve cold chain logistics in remote destinations
  • 5.6. Growing demand for combination vaccines covering multiple endemic diseases for multi-country itineraries
  • 5.7. Use of telemedicine platforms for remote pre-travel consultation and vaccine recommendation services
  • 5.8. Impact of regulatory harmonization efforts on streamlining cross border vaccine approval processes
  • 5.9. Development of eco-friendly and sustainable packaging solutions for international vaccine distribution
  • 5.10. Influence of post-pandemic travel surges on immunization resource allocation and prioritization strategies

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Travel Vaccines Market, by Vaccine Type

  • 8.1. Hepatitis A
  • 8.2. Hepatitis B
  • 8.3. Influenza
  • 8.4. Meningococcal
  • 8.5. Rabies
  • 8.6. Typhoid
  • 8.7. Yellow Fever

9. Travel Vaccines Market, by Form

  • 9.1. Injectable
  • 9.2. Oral

10. Travel Vaccines Market, by Age Group

  • 10.1. Adult
  • 10.2. Pediatric

11. Travel Vaccines Market, by End User

  • 11.1. Hospitals & Clinics
  • 11.2. Online Pharmacies
  • 11.3. Pharmacies
  • 11.4. Travel Clinics

12. Travel Vaccines Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Travel Vaccines Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Travel Vaccines Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. Competitive Landscape

  • 15.1. Market Share Analysis, 2024
  • 15.2. FPNV Positioning Matrix, 2024
  • 15.3. Competitive Analysis
    • 15.3.1. Sanofi S.A.
    • 15.3.2. GlaxoSmithKline plc
    • 15.3.3. Merck & Co., Inc.
    • 15.3.4. Pfizer Inc.
    • 15.3.5. Takeda Pharmaceutical Company Limited
    • 15.3.6. Valneva SE
    • 15.3.7. Bavarian Nordic A/S
    • 15.3.8. Bharat Biotech International Limited
    • 15.3.9. Serum Institute of India Private Limited
    • 15.3.10. Perusahaan Umum (Persero) Bio Farma

LIST OF FIGURES

  • FIGURE 1. GLOBAL TRAVEL VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL TRAVEL VACCINES MARKET SIZE, BY VACCINE TYPE, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL TRAVEL VACCINES MARKET SIZE, BY VACCINE TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL TRAVEL VACCINES MARKET SIZE, BY FORM, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL TRAVEL VACCINES MARKET SIZE, BY FORM, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL TRAVEL VACCINES MARKET SIZE, BY AGE GROUP, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL TRAVEL VACCINES MARKET SIZE, BY AGE GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL TRAVEL VACCINES MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL TRAVEL VACCINES MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL TRAVEL VACCINES MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 11. AMERICAS TRAVEL VACCINES MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. NORTH AMERICA TRAVEL VACCINES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. LATIN AMERICA TRAVEL VACCINES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. EUROPE, MIDDLE EAST & AFRICA TRAVEL VACCINES MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. EUROPE TRAVEL VACCINES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. MIDDLE EAST TRAVEL VACCINES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. AFRICA TRAVEL VACCINES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC TRAVEL VACCINES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. GLOBAL TRAVEL VACCINES MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASEAN TRAVEL VACCINES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GCC TRAVEL VACCINES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. EUROPEAN UNION TRAVEL VACCINES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. BRICS TRAVEL VACCINES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. G7 TRAVEL VACCINES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. NATO TRAVEL VACCINES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. GLOBAL TRAVEL VACCINES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. TRAVEL VACCINES MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 28. TRAVEL VACCINES MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. TRAVEL VACCINES MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL TRAVEL VACCINES MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL TRAVEL VACCINES MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL TRAVEL VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL TRAVEL VACCINES MARKET SIZE, BY VACCINE TYPE, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL TRAVEL VACCINES MARKET SIZE, BY HEPATITIS A, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL TRAVEL VACCINES MARKET SIZE, BY HEPATITIS A, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL TRAVEL VACCINES MARKET SIZE, BY HEPATITIS A, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL TRAVEL VACCINES MARKET SIZE, BY HEPATITIS A, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL TRAVEL VACCINES MARKET SIZE, BY HEPATITIS A, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL TRAVEL VACCINES MARKET SIZE, BY HEPATITIS A, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL TRAVEL VACCINES MARKET SIZE, BY HEPATITIS B, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL TRAVEL VACCINES MARKET SIZE, BY HEPATITIS B, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL TRAVEL VACCINES MARKET SIZE, BY HEPATITIS B, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL TRAVEL VACCINES MARKET SIZE, BY HEPATITIS B, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL TRAVEL VACCINES MARKET SIZE, BY HEPATITIS B, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL TRAVEL VACCINES MARKET SIZE, BY HEPATITIS B, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL TRAVEL VACCINES MARKET SIZE, BY INFLUENZA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL TRAVEL VACCINES MARKET SIZE, BY INFLUENZA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL TRAVEL VACCINES MARKET SIZE, BY INFLUENZA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL TRAVEL VACCINES MARKET SIZE, BY INFLUENZA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL TRAVEL VACCINES MARKET SIZE, BY INFLUENZA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL TRAVEL VACCINES MARKET SIZE, BY INFLUENZA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL TRAVEL VACCINES MARKET SIZE, BY MENINGOCOCCAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL TRAVEL VACCINES MARKET SIZE, BY MENINGOCOCCAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL TRAVEL VACCINES MARKET SIZE, BY MENINGOCOCCAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL TRAVEL VACCINES MARKET SIZE, BY MENINGOCOCCAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL TRAVEL VACCINES MARKET SIZE, BY MENINGOCOCCAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL TRAVEL VACCINES MARKET SIZE, BY MENINGOCOCCAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL TRAVEL VACCINES MARKET SIZE, BY RABIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL TRAVEL VACCINES MARKET SIZE, BY RABIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL TRAVEL VACCINES MARKET SIZE, BY RABIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL TRAVEL VACCINES MARKET SIZE, BY RABIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL TRAVEL VACCINES MARKET SIZE, BY RABIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL TRAVEL VACCINES MARKET SIZE, BY RABIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL TRAVEL VACCINES MARKET SIZE, BY TYPHOID, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL TRAVEL VACCINES MARKET SIZE, BY TYPHOID, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL TRAVEL VACCINES MARKET SIZE, BY TYPHOID, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL TRAVEL VACCINES MARKET SIZE, BY TYPHOID, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL TRAVEL VACCINES MARKET SIZE, BY TYPHOID, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL TRAVEL VACCINES MARKET SIZE, BY TYPHOID, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL TRAVEL VACCINES MARKET SIZE, BY YELLOW FEVER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL TRAVEL VACCINES MARKET SIZE, BY YELLOW FEVER, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL TRAVEL VACCINES MARKET SIZE, BY YELLOW FEVER, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL TRAVEL VACCINES MARKET SIZE, BY YELLOW FEVER, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL TRAVEL VACCINES MARKET SIZE, BY YELLOW FEVER, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL TRAVEL VACCINES MARKET SIZE, BY YELLOW FEVER, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL TRAVEL VACCINES MARKET SIZE, BY FORM, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL TRAVEL VACCINES MARKET SIZE, BY FORM, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL TRAVEL VACCINES MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL TRAVEL VACCINES MARKET SIZE, BY INJECTABLE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL TRAVEL VACCINES MARKET SIZE, BY INJECTABLE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL TRAVEL VACCINES MARKET SIZE, BY INJECTABLE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL TRAVEL VACCINES MARKET SIZE, BY INJECTABLE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL TRAVEL VACCINES MARKET SIZE, BY INJECTABLE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL TRAVEL VACCINES MARKET SIZE, BY ORAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL TRAVEL VACCINES MARKET SIZE, BY ORAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL TRAVEL VACCINES MARKET SIZE, BY ORAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL TRAVEL VACCINES MARKET SIZE, BY ORAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL TRAVEL VACCINES MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL TRAVEL VACCINES MARKET SIZE, BY ORAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL TRAVEL VACCINES MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL TRAVEL VACCINES MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL TRAVEL VACCINES MARKET SIZE, BY ADULT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL TRAVEL VACCINES MARKET SIZE, BY ADULT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL TRAVEL VACCINES MARKET SIZE, BY ADULT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL TRAVEL VACCINES MARKET SIZE, BY ADULT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL TRAVEL VACCINES MARKET SIZE, BY ADULT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL TRAVEL VACCINES MARKET SIZE, BY ADULT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL TRAVEL VACCINES MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL TRAVEL VACCINES MARKET SIZE, BY PEDIATRIC, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL TRAVEL VACCINES MARKET SIZE, BY PEDIATRIC, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL TRAVEL VACCINES MARKET SIZE, BY PEDIATRIC, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL TRAVEL VACCINES MARKET SIZE, BY PEDIATRIC, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL TRAVEL VACCINES MARKET SIZE, BY PEDIATRIC, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL TRAVEL VACCINES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL TRAVEL VACCINES MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL TRAVEL VACCINES MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL TRAVEL VACCINES MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL TRAVEL VACCINES MARKET SIZE, BY HOSPITALS & CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL TRAVEL VACCINES MARKET SIZE, BY HOSPITALS & CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL TRAVEL VACCINES MARKET SIZE, BY HOSPITALS & CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL TRAVEL VACCINES MARKET SIZE, BY HOSPITALS & CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL TRAVEL VACCINES MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL TRAVEL VACCINES MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL TRAVEL VACCINES MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL TRAVEL VACCINES MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL TRAVEL VACCINES MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL TRAVEL VACCINES MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL TRAVEL VACCINES MARKET SIZE, BY PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL TRAVEL VACCINES MARKET SIZE, BY PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL TRAVEL VACCINES MARKET SIZE, BY PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL TRAVEL VACCINES MARKET SIZE, BY PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL TRAVEL VACCINES MARKET SIZE, BY PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL TRAVEL VACCINES MARKET SIZE, BY PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL TRAVEL VACCINES MARKET SIZE, BY TRAVEL CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL TRAVEL VACCINES MARKET SIZE, BY TRAVEL CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL TRAVEL VACCINES MARKET SIZE, BY TRAVEL CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL TRAVEL VACCINES MARKET SIZE, BY TRAVEL CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL TRAVEL VACCINES MARKET SIZE, BY TRAVEL CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL TRAVEL VACCINES MARKET SIZE, BY TRAVEL CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL TRAVEL VACCINES MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL TRAVEL VACCINES MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 105. AMERICAS TRAVEL VACCINES MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 106. AMERICAS TRAVEL VACCINES MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 107. AMERICAS TRAVEL VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
  • TABLE 108. AMERICAS TRAVEL VACCINES MARKET SIZE, BY VACCINE TYPE, 2025-2032 (USD MILLION)
  • TABLE 109. AMERICAS TRAVEL VACCINES MARKET SIZE, BY FORM, 2018-2024 (USD MILLION)
  • TABLE 110. AMERICAS TRAVEL VACCINES MARKET SIZE, BY FORM, 2025-2032 (USD MILLION)
  • TABLE 111. AMERICAS TRAVEL VACCINES MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 112. AMERICAS TRAVEL VACCINES MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 113. AMERICAS TRAVEL VACCINES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 114. AMERICAS TRAVEL VACCINES MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 115. NORTH AMERICA TRAVEL VACCINES MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 116. NORTH AMERICA TRAVEL VACCINES MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 117. NORTH AMERICA TRAVEL VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
  • TABLE 118. NORTH AMERICA TRAVEL VACCINES MARKET SIZE, BY VACCINE TYPE, 2025-2032 (USD MILLION)
  • TABLE 119. NORTH AMERICA TRAVEL VACCINES MARKET SIZE, BY FORM, 2018-2024 (USD MILLION)
  • TABLE 120. NORTH AMERICA TRAVEL VACCINES MARKET SIZE, BY FORM, 2025-2032 (USD MILLION)
  • TABLE 121. NORTH AMERICA TRAVEL VACCINES MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 122. NORTH AMERICA TRAVEL VACCINES MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 123. NORTH AMERICA TRAVEL VACCINES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 124. NORTH AMERICA TRAVEL VACCINES MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 125. LATIN AMERICA TRAVEL VACCINES MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 126. LATIN AMERICA TRAVEL VACCINES MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 127. LATIN AMERICA TRAVEL VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
  • TABLE 128. LATIN AMERICA TRAVEL VACCINES MARKET SIZE, BY VACCINE TYPE, 2025-2032 (USD MILLION)
  • TABLE 129. LATIN AMERICA TRAVEL VACCINES MARKET SIZE, BY FORM, 2018-2024 (USD MILLION)
  • TABLE 130. LATIN AMERICA TRAVEL VACCINES MARKET SIZE, BY FORM, 2025-2032 (USD MILLION)
  • TABLE 131. LATIN AMERICA TRAVEL VACCINES MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 132. LATIN AMERICA TRAVEL VACCINES MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 133. LATIN AMERICA TRAVEL VACCINES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 134. LATIN AMERICA TRAVEL VACCINES MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 135. EUROPE, MIDDLE EAST & AFRICA TRAVEL VACCINES MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 136. EUROPE, MIDDLE EAST & AFRICA TRAVEL VACCINES MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 137. EUROPE, MIDDLE EAST & AFRICA TRAVEL VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
  • TABLE 138. EUROPE, MIDDLE EAST & AFRICA TRAVEL VACCINES MARKET SIZE, BY VACCINE TYPE, 2025-2032 (USD MILLION)
  • TABLE 139. EUROPE, MIDDLE EAST & AFRICA TRAVEL VACCINES MARKET SIZE, BY FORM, 2018-2024 (USD MILLION)
  • TABLE 140. EUROPE, MIDDLE EAST & AFRICA TRAVEL VACCINES MARKET SIZE, BY FORM, 2025-2032 (USD MILLION)
  • TABLE 141. EUROPE, MIDDLE EAST & AFRICA TRAVEL VACCINES MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 142. EUROPE, MIDDLE EAST & AFRICA TRAVEL VACCINES MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 143. EUROPE, MIDDLE EAST & AFRICA TRAVEL VACCINES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 144. EUROPE, MIDDLE EAST & AFRICA TRAVEL VACCINES MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 145. EUROPE TRAVEL VACCINES MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 146. EUROPE TRAVEL VACCINES MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 147. EUROPE TRAVEL VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
  • TABLE 148. EUROPE TRAVEL VACCINES MARKET SIZE, BY VACCINE TYPE, 2025-2032 (USD MILLION)
  • TABLE 149. EUROPE TRAVEL VACCINES MARKET SIZE, BY FORM, 2018-2024 (USD MILLION)
  • TABLE 150. EUROPE TRAVEL VACCINES MARKET SIZE, BY FORM, 2025-2032 (USD MILLION)
  • TABLE 151. EUROPE TRAVEL VACCINES MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 152. EUROPE TRAVEL VACCINES MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 153. EUROPE TRAVEL VACCINES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 154. EUROPE TRAVEL VACCINES MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 155. MIDDLE EAST TRAVEL VACCINES MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 156. MIDDLE EAST TRAVEL VACCINES MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 157. MIDDLE EAST TRAVEL VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
  • TABLE 158. MIDDLE EAST TRAVEL VACCINES MARKET SIZE, BY VACCINE TYPE, 2025-2032 (USD MILLION)
  • TABLE 159. MIDDLE EAST TRAVEL VACCINES MARKET SIZE, BY FORM, 2018-2024 (USD MILLION)
  • TABLE 160. MIDDLE EAST TRAVEL VACCINES MARKET SIZE, BY FORM, 2025-2032 (USD MILLION)
  • TABLE 161. MIDDLE EAST TRAVEL VACCINES MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 162. MIDDLE EAST TRAVEL VACCINES MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 163. MIDDLE EAST TRAVEL VACCINES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 164. MIDDLE EAST TRAVEL VACCINES MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 165. AFRICA TRAVEL VACCINES MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 166. AFRICA TRAVEL VACCINES MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 167. AFRICA TRAVEL VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
  • TABLE 168. AFRICA TRAVEL VACCINES MARKET SIZE, BY VACCINE TYPE, 2025-2032 (USD MILLION)
  • TABLE 169. AFRICA TRAVEL VACCINES MARKET SIZE, BY FORM, 2018-2024 (USD MILLION)
  • TABLE 170. AFRICA TRAVEL VACCINES MARKET SIZE, BY FORM, 2025-2032 (USD MILLION)
  • TABLE 171. AFRICA TRAVEL VACCINES MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 172. AFRICA TRAVEL VACCINES MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 173. AFRICA TRAVEL VACCINES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 174. AFRICA TRAVEL VACCINES MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 175. ASIA-PACIFIC TRAVEL VACCINES MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 176. ASIA-PACIFIC TRAVEL VACCINES MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 177. ASIA-PACIFIC TRAVEL VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
  • TABLE 178. ASIA-PACIFIC TRAVEL VACCINES MARKET SIZE, BY VACCINE TYPE, 2025-2032 (USD MILLION)
  • TABLE 179. ASIA-PACIFIC TRAVEL VACCINES MARKET SIZE, BY FORM, 2018-2024 (USD MILLION)
  • TABLE 180. ASIA-PACIFIC TRAVEL VACCINES MARKET SIZE, BY FORM, 2025-2032 (USD MILLION)
  • TABLE 181. ASIA-PACIFIC TRAVEL VACCINES MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 182. ASIA-PACIFIC TRAVEL VACCINES MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 183. ASIA-PACIFIC TRAVEL VACCINES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 184. ASIA-PACIFIC TRAVEL VACCINES MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 185. GLOBAL TRAVEL VACCINES MARKET SIZE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL TRAVEL VACCINES MARKET SIZE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 187. ASEAN TRAVEL VACCINES MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 188. ASEAN TRAVEL VACCINES MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 189. ASEAN TRAVEL VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
  • TABLE 190. ASEAN TRAVEL VACCINES MARKET SIZE, BY VACCINE TYPE, 2025-2032 (USD MILLION)
  • TABLE 191. ASEAN TRAVEL VACCINES MARKET SIZE, BY FORM, 2018-2024 (USD MILLION)
  • TABLE 192. ASEAN TRAVEL VACCINES MARKET SIZE, BY FORM, 2025-2032 (USD MILLION)
  • TABLE 193. ASEAN TRAVEL VACCINES MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 194. ASEAN TRAVEL VACCINES MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 195. ASEAN TRAVEL VACCINES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 196. ASEAN TRAVEL VACCINES MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 197. GCC TRAVEL VACCINES MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 198. GCC TRAVEL VACCINES MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 199. GCC TRAVEL VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
  • TABLE 200. GCC TRAVEL VACCINES MARKET SIZE, BY VACCINE TYPE, 2025-2032 (USD MILLION)
  • TABLE 201. GCC TRAVEL VACCINES MARKET SIZE, BY FORM, 2018-2024 (USD MILLION)
  • TABLE 202. GCC TRAVEL VACCINES MARKET SIZE, BY FORM, 2025-2032 (USD MILLION)
  • TABLE 203. GCC TRAVEL VACCINES MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 204. GCC TRAVEL VACCINES MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 205. GCC TRAVEL VACCINES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 206. GCC TRAVEL VACCINES MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 207. EUROPEAN UNION TRAVEL VACCINES MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 208. EUROPEAN UNION TRAVEL VACCINES MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 209. EUROPEAN UNION TRAVEL VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
  • TABLE 210. EUROPEAN UNION TRAVEL VACCINES MARKET SIZE, BY VACCINE TYPE, 2025-2032 (USD MILLION)
  • TABLE 211. EUROPEAN UNION TRAVEL VACCINES MARKET SIZE, BY FORM, 2018-2024 (USD MILLION)
  • TABLE 212. EUROPEAN UNION TRAVEL VACCINES MARKET SIZE, BY FORM, 2025-2032 (USD MILLION)
  • TABLE 213. EUROPEAN UNION TRAVEL VACCINES MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 214. EUROPEAN UNION TRAVEL VACCINES MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 215. EUROPEAN UNION TRAVEL VACCINES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 216. EUROPEAN UNION TRAVEL VACCINES MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 217. BRICS TRAVEL VACCINES MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 218. BRICS TRAVEL VACCINES MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 219. BRICS TRAVEL VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
  • TABLE 220. BRICS TRAVEL VACCINES MARKET SIZE, BY VACCINE TYPE, 2025-2032 (USD MILLION)
  • TABLE 221. BRICS TRAVEL VACCINES MARKET SIZE, BY FORM, 2018-2024 (USD MILLION)
  • TABLE 222. BRICS TRAVEL VACCINES MARKET SIZE, BY FORM, 2025-2032 (USD MILLION)
  • TABLE 223. BRICS TRAVEL VACCINES MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 224. BRICS TRAVEL VACCINES MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 225. BRICS TRAVEL VACCINES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 226. BRICS TRAVEL VACCINES MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 227. G7 TRAVEL VACCINES MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 228. G7 TRAVEL VACCINES MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 229. G7 TRAVEL VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
  • TABLE 230. G7 TRAVEL VACCINES MARKET SIZE, BY VACCINE TYPE, 2025-2032 (USD MILLION)
  • TABLE 231. G7 TRAVEL VACCINES MARKET SIZE, BY FORM, 2018-2024 (USD MILLION)
  • TABLE 232. G7 TRAVEL VACCINES MARKET SIZE, BY FORM, 2025-2032 (USD MILLION)
  • TABLE 233. G7 TRAVEL VACCINES MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 234. G7 TRAVEL VACCINES MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 235. G7 TRAVEL VACCINES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 236. G7 TRAVEL VACCINES MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 237. NATO TRAVEL VACCINES MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 238. NATO TRAVEL VACCINES MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 239. NATO TRAVEL VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
  • TABLE 240. NATO TRAVEL VACCINES MARKET SIZE, BY VACCINE TYPE, 2025-2032 (USD MILLION)
  • TABLE 241. NATO TRAVEL VACCINES MARKET SIZE, BY FORM, 2018-2024 (USD MILLION)
  • TABLE 242. NATO TRAVEL VACCINES MARKET SIZE, BY FORM, 2025-2032 (USD MILLION)
  • TABLE 243. NATO TRAVEL VACCINES MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 244. NATO TRAVEL VACCINES MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 245. NATO TRAVEL VACCINES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 246. NATO TRAVEL VACCINES MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 247. GLOBAL TRAVEL VACCINES MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 248. GLOBAL TRAVEL VACCINES MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 249. UNITED STATES TRAVEL VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
  • TABLE 250. UNITED STATES TRAVEL VACCINES MARKET SIZE, BY VACCINE TYPE, 2025-2032 (USD MILLION)
  • TABLE 251. UNITED STATES TRAVEL VACCINES MARKET SIZE, BY FORM, 2018-2024 (USD MILLION)
  • TABLE 252. UNITED STATES TRAVEL VACCINES MARKET SIZE, BY FORM, 2025-2032 (USD MILLION)
  • TABLE 253. UNITED STATES TRAVEL VACCINES MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 254. UNITED STATES TRAVEL VACCINES MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 255. UNITED STATES TRAVEL VACCINES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 256. UNITED STATES TRAVEL VACCINES MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 257. CANADA TRAVEL VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
  • TABLE 258. CANADA TRAVEL VACCINES MARKET SIZE, BY VACCINE TYPE, 2025-2032 (USD MILLION)
  • TABLE 259. CANADA TRAVEL VACCINES MARKET SIZE, BY FORM, 2018-2024 (USD MILLION)
  • TABLE 260. CANADA TRAVEL VACCINES MARKET SIZE, BY FORM, 2025-2032 (USD MILLION)
  • TABLE 261. CANADA TRAVEL VACCINES MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 262. CANADA TRAVEL VACCINES MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 263. CANADA TRAVEL VACCINES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 264. CANADA TRAVEL VACCINES MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 265. MEXICO TRAVEL VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
  • TABLE 266. MEXICO TRAVEL VACCINES MARKET SIZE, BY VACCINE TYPE, 2025-2032 (USD MILLION)
  • TABLE 267. MEXICO TRAVEL VACCINES MARKET SIZE, BY FORM, 2018-2024 (USD MILLION)
  • TABLE 268. MEXICO TRAVEL VACCINES MARKET SIZE, BY FORM, 2025-2032 (USD MILLION)
  • TABLE 269. MEXICO TRAVEL VACCINES MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 270. MEXICO TRAVEL VACCINES MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 271. MEXICO TRAVEL VACCINES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 272. MEXICO TRAVEL VACCINES MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 273. BRAZIL TRAVEL VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
  • TABLE 274. BRAZIL TRAVEL VACCINES MARKET SIZE, BY VACCINE TYPE, 2025-2032 (USD MILLION)
  • TABLE 275. BRAZIL TRAVEL VACCINES MARKET SIZE, BY FORM, 2018-2024 (USD MILLION)
  • TABLE 276. BRAZIL TRAVEL VACCINES MARKET SIZE, BY FORM, 2025-2032 (USD MILLION)
  • TABLE 277. BRAZIL TRAVEL VACCINES MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 278. BRAZIL TRAVEL VACCINES MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 279. BRAZIL TRAVEL VACCINES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 280. BRAZIL TRAVEL VACCINES MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 281. UNITED KINGDOM TRAVEL VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
  • TABLE 282. UNITED KINGDOM TRAVEL VACCINES MARKET SIZE, BY VACCINE TYPE, 2025-2032 (USD MILLION)
  • TABLE 283. UNITED KINGDOM TRAVEL VACCINES MARKET SIZE, BY FORM, 2018-2024 (USD MILLION)
  • TABLE 284. UNITED KINGDOM TRAVEL VACCINES MARKET SIZE, BY FORM, 2025-2032 (USD MILLION)
  • TABLE 285. UNITED KINGDOM TRAVEL VACCINES MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 286. UNITED KINGDOM TRAVEL VACCINES MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 287. UNITED KINGDOM TRAVEL VACCINES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 288. UNITED KINGDOM TRAVEL VACCINES MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 289. GERMANY TRAVEL VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
  • TABLE 290. GERMANY TRAVEL VACCINES MARKET SIZE, BY VACCINE TYPE, 2025-2032 (USD MILLION)
  • TABLE 291. GERMANY TRAVEL VACCINES MARKET SIZE, BY FORM, 2018-2024 (USD MILLION)
  • TABLE 292. GERMANY TRAVEL VACCINES MARKET SIZE, BY FORM, 2025-2032 (USD MILLION)
  • TABLE 293. GERMANY TRAVEL VACCINES MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 294. GERMANY TRAVEL VACCINES MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 295. GERMANY TRAVEL VACCINES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 296. GERMANY TRAVEL VACCINES MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 297. FRANCE TRAVEL VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
  • TABLE 298. FRANCE TRAVEL VACCINES MARKET SIZE, BY VACCINE TYPE, 2025-2032 (USD MILLION)
  • TABLE 299. FRANCE TRAVEL VACCINES MARKET SIZE, BY FORM, 2018-2024 (USD MILLION)
  • TABLE 300. FRANCE TRAVEL VACCINES MARKET SIZE, BY FORM, 2025-2032 (USD MILLION)
  • TABLE 301. FRANCE TRAVEL VACCINES MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 302. FRANCE TRAVEL VACCINES MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 303. FRANCE TRAVEL VACCINES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 304. FRANCE TRAVEL VACCINES MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 305. RUSSIA TRAVEL VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
  • TABLE 306. RUSSIA TRAVEL VACCINES MARKET SIZE, BY VACCINE TYPE, 2025-2032 (USD MILLION)
  • TABLE 307. RUSSIA TRAVEL VACCINES MARKET SIZE, BY FORM, 2018-2024 (USD MILLION)
  • TABLE 308. RUSSIA TRAVEL VACCINES MARKET SIZE, BY FORM, 2025-2032 (USD MILLION)
  • TABLE 309. RUSSIA TRAVEL VACCINES MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 310. RUSSIA TRAVEL VACCINES MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 311. RUSSIA TRAVEL VACCINES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 312. RUSSIA TRAVEL VACCINES MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 313. ITALY TRAVEL VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
  • TABLE 314. ITALY TRAVEL VACCINES MARKET SIZE, BY VACCINE TYPE, 2025-2032 (USD MILLION)
  • TABLE 315. ITALY TRAVEL VACCINES MARKET SIZE, BY FORM, 2018-2024 (USD MILLION)
  • TABLE 316. ITALY TRAVEL VACCINES MARKET SIZE, BY FORM, 2025-2032 (USD MILLION)
  • TABLE 317. ITALY TRAVEL VACCINES MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 318. ITALY TRAVEL VACCINES MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 319. ITALY TRAVEL VACCINES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 320. ITALY TRAVEL VACCINES MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 321. SPAIN TRAVEL VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
  • TABLE 322. SPAIN TRAVEL VACCINES MARKET SIZE, BY VACCINE TYPE, 2025-2032 (USD MILLION)
  • TABLE 323. SPAIN TRAVEL VACCINES MARKET SIZE, BY FORM, 2018-2024 (USD MILLION)
  • TABLE 324. SPAIN TRAVEL VACCINES MARKET SIZE, BY FORM, 2025-2032 (USD MILLION)
  • TABLE 325. SPAIN TRAVEL VACCINES MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 326. SPAIN TRAVEL VACCINES MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 327. SPAIN TRAVEL VACCINES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 328. SPAIN TRAVEL VACCINES MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 329. CHINA TRAVEL VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
  • TABLE 330. CHINA TRAVEL VACCINES MARKET SIZE, BY VACCINE TYPE, 2025-2032 (USD MILLION)
  • TABLE 331. CHINA TRAVEL VACCINES MARKET SIZE, BY FORM, 2018-2024 (USD MILLION)
  • TABLE 332. CHINA TRAVEL VACCINES MARKET SIZE, BY FORM, 2025-2032 (USD MILLION)
  • TABLE 333. CHINA TRAVEL VACCINES MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 334. CHINA TRAVEL VACCINES MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 335. CHINA TRAVEL VACCINES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 336. CHINA TRAVEL VACCINES MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 337. INDIA TRAVEL VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
  • TABLE 338. INDIA TRAVEL VACCINES MARKET SIZE, BY VACCINE TYPE, 2025-2032 (USD MILLION)
  • TABLE 339. INDIA TRAVEL VACCINES MARKET SIZE, BY FORM, 2018-2024 (USD MILLION)
  • TABLE 340. INDIA TRAVEL VACCINES MARKET SIZE, BY FORM, 2025-2032 (USD MILLION)
  • TABLE 341. INDIA TRAVEL VACCINES MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 342. INDIA TRAVEL VACCINES MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 343. INDIA TRAVEL VACCINES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 344. INDIA TRAVEL VACCINES MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 345. JAPAN TRAVEL VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
  • TABLE 346. JAPAN TRAVEL VACCINES MARKET SIZE, BY VACCINE TYPE, 2025-2032 (USD MILLION)
  • TABLE 347. JAPAN TRAVEL VACCINES MARKET SIZE, BY FORM, 2018-2024 (USD MILLION)
  • TABLE 348. JAPAN TRAVEL VACCINES MARKET SIZE, BY FORM, 2025-2032 (USD MILLION)
  • TABLE 349. JAPAN TRAVEL VACCINES MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 350. JAPAN TRAVEL VACCINES MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 351. JAPAN TRAVEL VACCINES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 352. JAPAN TRAVEL VACCINES MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 353. AUSTRALIA TRAVEL VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
  • TABLE 354. AUSTRALIA TRAVEL VACCINES MARKET SIZE, BY VACCINE TYPE, 2025-2032 (USD MILLION)
  • TABLE 355. AUSTRALIA TRAVEL VACCINES MARKET SIZE, BY FORM, 2018-2024 (USD MILLION)
  • TABLE 356. AUSTRALIA TRAVEL VACCINES MARKET SIZE, BY FORM, 2025-2032 (USD MILLION)
  • TABLE 357. AUSTRALIA TRAVEL VACCINES MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 358. AUSTRALIA TRAVEL VACCINES MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 359. AUSTRALIA TRAVEL VACCINES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 360. AUSTRALIA TRAVEL VACCINES MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 361. SOUTH KOREA TRAVEL VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
  • TABLE 362. SOUTH KOREA TRAVEL VACCINES MARKET SIZE, BY VACCINE TYPE, 2025-2032 (USD MILLION)
  • TABLE 363. SOUTH KOREA TRAVEL VACCINES MARKET SIZE, BY FORM, 2018-2024 (USD MILLION)
  • TABLE 364. SOUTH KOREA TRAVEL VACCINES MARKET SIZE, BY FORM, 2025-2032 (USD MILLION)
  • TABLE 365. SOUTH KOREA TRAVEL VACCINES MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 366. SOUTH KOREA TRAVEL VACCINES MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 367. SOUTH KOREA TRAVEL VACCINES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 368. SOUTH KOREA TRAVEL VACCINES MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 369. TRAVEL VACCINES MARKET SHARE, BY KEY PLAYER, 2024
  • TABLE 370. TRAVEL VACCINES MARKET, FPNV POSITIONING MATRIX, 2024